Dapagliflozin and Empagliflozin are licensed for use in Symptomatic chronic heart failure with the following NICE TAs associated with them:

• NICE TA679 Dapagliflozin for treating chronic heart failure with reduced ejection fraction (February 2021)
• NICE TA902  Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (June 2023)
• NICE TA773  Empagliflozin for treating chronic heart failure with reduced ejection fraction (March 2022)
• NICE TA929  Empagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction (November 2023)

K&M Implementation of NICE TA’s – SGLT2 inhibitors (Dapagliflozin & Empagliflozin) in the treatment of chronic heart failure

In order to ensure clarity for clinicians and promote equitable access, the Kent and Medway Medicines Optimisation Team recommends that:

1. Dapagliflozin and Empagliflozin, when used to treat chronic heart failure with reduced ejection fraction, are initiated by/on the advice of a heart failure specialist, with follow on prescribing in primary care.

2. Where specialist community heart failure teams exist, dapagliflozin or empagliflozin may be initiated by the team following consultation with and continued oversight by a (consultant led) specialist heart failure multidisciplinary team (MDT), with a clear audit trail of such consultation.

3. For patients with comorbidities e.g. diabetes, multi-speciality MDTs would be appropriate.

4. Monitoring requirements and discontinuation criteria should be set out at initiation and clearly communicated to the clinician who continues with dapagliflozin prescribing.

 Chronic Kidney Disease (CKD) in Adults

For Primary Care Guidance - for Chronic Kidney Disease (CKD) in Adults and NICE TA775 for treating chronic kidney disease  Click Here

Empagliflozin for treating CKD in accordance with NICE TA942